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Clonal hematopoiesis driven by somatic heterozygous TET2 loss is linked to malignant
degeneration via consequent aberrant DNA methylation, and possibly to cardiovascular
disease via increased cytokine and chemokine expression as reported in mice. Here, we
discover a germline TET2 mutation in a lymphoma family. We observe neither unusual
predisposition to atherosclerosis nor abnormal pro-inflammatory cytokine or chemokine
expression. The latter finding is confirmed in cells from three additional unrelated TET2
germline mutation carriers. The TET2 defect elevates blood DNA methylation levels, espe-
cially at active enhancers and cell-type specific regulatory regions with binding sequences of
master transcription factors involved in hematopoiesis. The regions display reduced
methylation relative to all open chromatin regions in four DNMT3A germline mutation car-
riers, potentially due to TET2-mediated oxidation. Our findings provide insight into the
interplay between epigenetic modulators and transcription factor activity in hematological
neoplasia, but do not confirm the putative role of TET2 in atherosclerosis.
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C lonal hematopoiesis (CH) is common in aged individualsand bears implications to health through risk of malignantdegeneration of cells1 and possible risk of cardiovascular
disease (CVD)2–4. Heterozygous tet methylcytosine dioxygenase 2
(TET2) and DNA methyltransferase 3A (DNMT3A) mutations
are the two most frequent drivers of CH1, and mechanistic studies
connecting CH and CVD revolve around Tet2-deficient models.
Heterozygous and homozygous Tet2 loss in mice accelerates
atherosclerosis, possibly via enhanced macrophage-driven
inflammation4,5. Acceleration of heart failure has also been sug-
gested6. In particular, two macrophage-mediated mechanisms
have been proposed: exacerbated expression and inflammasome-
mediated secretion of interleukin (IL)-1β, as well as aberrant
chemokine expression signature4,5. These findings have promoted
hopes for population level prevention of CVD through detection
of individuals with TET2-mutation-positive clones and sub-
sequent use of cholesterol-lowering medications or compounds
targeting IL-1β and other inflammatory pathways2,4,5. Thus,
understanding whether heterozygous TET2 loss is associated with
CVD in humans, and if yes through what mechanism, is of
utmost importance.
DNA methylation is a key regulator of cell development and
differentiation, and its aberrations are an essential factor in
hematological neoplasia7. DNA methylation is mediated by DNA
methyltransferase enzymes that transfer a methyl group to carbon
atom 5 of cytosine nucleotide at CpG dinucleotides or CxG context
at gene bodies, x standing for bases T, A, or C8. In DNA deme-
thylation, TET protein family of dioxygenases catalyze the oxidi-
zation of 5-methylcytosine (5-mC) to 5-hydroxymethylcytosine (5-
hmC), 5-formylcytosine, and 5-carboxylcytosine, acting as an
initiator of DNA demethylation cascade subsequently resulting in
an unmodified cytosine8.
In addition to CH, somatic frameshift, nonsense, and missense
TET2 mutations are commonly seen for example in myelodys-
plastic syndrome (6–26% prevalence), acute myeloid leukemia
(AML; 12–27% in adult de novo AML), chronic myelomonocytic
leukemia (20–58%), and angioimmunoblastic T-cell lymphoma
(33–83%)8. Although a key event, TET2 loss alone is not suffi-
cient to trigger malignancy7. Careful examination of individuals
with a germline mutation could provide valuable insight into the
effects of TET2 loss in humans. In this study, we observed the
effects of constitutional heterozygous TET2 loss in a unique
pedigree of seven carriers segregating a truncating TET2 germ-
line mutation, as well as one case of de novo TET2 germline
mutation. For these individuals, extensive clinical documentation
was available. Methylation analysis of four individuals with a
DNMT3A germline mutation as well as analysis of inflammatory
response in two additional TET2 germline mutation carriers
reported earlier by Schaub et al.9 provided further context to the
results.
Results
Study subjects. The Finnish family segregating a TET2 germline
mutation is presented in Fig. 1a. Ly1 was diagnosed with nodular
lymphocyte predominant Hodgkin lymphoma (NLPHL) at age 46
(Supplementary Table 1, Supplementary Fig. 1), and Ly2 at age
45. At age 52, Ly2 experienced a relapse diagnosed as T-cell-rich
B-cell lymphoma. Ly3 was diagnosed with NLPHL at age 39.
Relapse at age 41 was diagnosed as mixed-cellular Hodgkin
lymphoma. Clinical bone marrow examination was done twice
(with 7 years’ time interval) for Ly1 and Ly2 after lymphoma
diagnosis. As the only finding of note, Ly2 had slightly hyper-
plastic bone marrow in the second examination. Whole-genome
(Ly1) and exome (Ly2 and Ly3) sequencing analysis revealed a
heterozygous one-base deletion NM_001127208.2:c.4500delA in
TET2 (Fig. 1b, Supplementary Table 2). The mother of Ly1, Ly2,
and Ly3 was found to be a carrier of the deletion based on
analysis of archival tissue DNA, and three further carriers (Ly9,
Ly11, and Ly14) were found in the next generations. The deletion
is similar to those often seen in somatic form in hematological
neoplasia and causes a frameshift at lysine 1500 residue, resulting
in a premature stop codon 70 residues later (NP_001120680.1:p.
Lys1500AsnfsTer71) (Fig. 1c). An AML patient has been found
with the same mutation previously10. Multiple amino-acid resi-
dues critical for the structural integrity of TET211 are lost due to
the deletion (Fig. 1d–f), and although both alleles are expressed at
the mRNA level (Supplementary Fig. 2), the truncation leads to
heterozygous loss of TET2 at the protein level (Fig. 1g, Supple-
mentary Fig. 3). TET2 c.4500delA (hereafter TET2delA) was
absent in 5197 in-house controls, the Exome Aggregation Con-
sortium dataset (version 0.2; http://exac.broadinstitute.org/), and
in 80,000 individuals in the Genome Aggregation Database
(version 2.0; http://gnomad.broadinstitute.org/).
Through Northern Finland Intellectual Disability (NFID)
Cohort, we could identify a carrier of de novo nonsense mutation
in TET2 (NM_001127208.2:c.1471C>T, NP_001120680.1:p.
Gln491Ter; hereafter individual Id1 with TET2X mutation). His
developmental milestones had been normal except for linguistic
skills, and he received speech therapy until age 7. Comprehensive
etiological examinations including copy number analysis did not
reveal the cause of developmental delay12. He was diagnosed with
mild mental retardation at age 7 and had features of attention
deficit hyperactivity disorder. According to the latest examination
by Wechsler Intelligence Scale For Children–IV at age 16, he had
reached normal cognitive skills apart from verbal comprehension.
His older sister had experienced a delay in speech development
but managed in standard school education. The parents were
confirmed as TET2X-negative by Sanger sequencing, and the
patient’s germline status was confirmed from saliva-derived
DNA.
To provide context to molecular findings in the TET2 mutation
carriers, DNA from non-carrier relatives, unrelated controls, as
well as from four DNMT3A germline mutation carriers from
NFID Cohort displaying features of Tatton-Brown-Rahman
syndrome13 were available for methylation analyses (Supplemen-
tary Table 3). In addition, we had the opportunity to study
immune responses in blood monocytes isolated from two carriers
of a heterozygous 4 base pair (bp) deletion in TET2 (hereafter
TET2del4) reported earlier by Schaub et al.9 (Fig. 1c).
Blood DNA methylation. Since deficient DNA demethylation is
the key consequence of TET2 mutations in hematological
neoplasia14,15, we compared blood DNA methylation by targeted
and whole-genome bisulfite sequencing (WGBS) in TET2 muta-
tion carriers and non-carriers (Supplementary Fig. 4, Supple-
mentary Tables 3, and 4). For comparisons between TET2delA
carriers and mutation-free controls, targeted data from 5 carriers
and 10 controls were utilized, as the higher number of samples
reduces the likelihood that changes are caused by disproportions
in cell types between the two groups. WGBS data, created from
the three lymphoma-free TET2delA carriers and three age-
matched controls, were used for genomic enrichment analyses
due to the higher number of data points and because the chro-
matin annotation of affected regions after TET2 loss is likely
identical in different cell types.
TET2delA carriers displayed a significantly higher degree of
overall hypermethylation (two-sided Wilcoxon rank sum test,
p-value 0.003) and decreased hypomethylation (two-sided
Wilcoxon rank sum test, p-value 0.01), compatible with
demethylation deficiency (Fig. 2a, Supplementary Table 5).
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Altogether 644/660 (97.6%) of differentially methylated regions
(DMRs) between TET2delA carriers and controls were
hypermethylated (Supplementary Data 1). To confirm that
similar changes are not found in carriers of common TET2
single-nucleotide polymorphisms (SNPs), we compared carriers
of heterozygous TET2 p.Leu1721Trp and p.Pro363Leu (n= 4;
rs34402524 and rs17253672 found in the same haplotype) to
non-carriers (n= 11), derived from two Finnish families. Blood
DNA methylation of all 15 individuals was measured by
targeted bisulfite sequencing similar to TET2delA carriers and
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Fig. 1 TET2 c.4500delA causes loss of the protein. a Pedigree (details modified for confidentiality) showing TET2 c.4500delA (TET2delA) statuses;
mutation carriers are marked with +/− and wild-type individuals with +/+. Solid square (male) or circle (female) depicts patients with lymphoma.
b Electropherograms of TET2delA-mutated and wild-type sample. c (Upper section) Somatic frameshifts or pathogenic substitutions along TET2 in
hematopoietic and lymphoid tissue malignancies from COSMIC database (release v81). (Lower section) Protein domain structure of TET2 from Hu et al.11.
The C-terminal catalytic domain of TET2 comprises Cys-rich N-terminal (Cys-N) and C-terminal (Cys-C) subdomains, and a double-stranded β helix
(DSBH) domain. Locations of germline frameshift mutations identified in this study and previously (Schaub et al.9) are shown. d–f Cartoon representation
of the catalytic domain of human TET2 complexed with methylated DNA (PDB entry 4nm6). Overall structure of the wild-type protein (d). DNA is colored
with blue, flanking Cys-rich domains are colored with light and dark orange, the DSBH core of the protein is colored with cyan and pink, the latter depicting
the sequence lost due to the TET2delA mutation. The predicted loss includes residues involved in formation of the DSBH domain such as H1912 involved in
coordination of Zn3-ion (e), as well as residues R1896 and S1898 critical for binding the substrate N-oxalyglycine (NOG) (f), H1881 involved in
coordination of Fe-ion (f), and Y1902 and H1904 interacting with 5-methylcytosine. Proper folding of the mutant protein lacking these critical amino acids
appears highly unlikely based on the structure. N-oxalyglycine, 5-methylcytosine, and residues mentioned above are shown with stick representation. An
iron and three zinc ions are shown as brown and gray balls, respectively. g Representative western blot of TET2 from lymphoblastoid cells of three
TET2delA mutation carriers and three wild-type individuals of the family. The graph shows the quantification of TET2 protein normalized to the vinculin.
Bars represent the mean ± s.d. of TET2 intensities
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controls. No difference in the number of hypermethylated (two-
sided Wilcoxon rank sum test, p-value 0.5714) nor hypomethy-
lated (two-sided Wilcoxon rank sum test, p-value 0.1773) CpG
sites was observed between the groups. Lymphoma patients
(Ly1 and Ly2) and cancer-free TET2delA carriers (Ly9, Ly11,
and Ly14) were also compared and no skewing toward
hypermethylation was observed, although the results should
be interpreted with caution due to low number of individuals in
this comparison (Supplementary Data 2). The demethylation
deficiency caused by heterozygous TET2 loss was further
confirmed by WGBS. Hypermethylation was more prominent
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TET2delA carriers and TET2X carrier were compared to age-
matched non-carriers (Fig. 2b–f). While repetitive regions of
the genome cannot be evaluated with short reads, the detected
hypermethylated CpG sites located mostly at CpG islands of the
genome (Supplementary Fig. 5a).
Next, we examined whether the hypermethylation in TET2X
and TET2delA carriers was enriched in regions with regulatory
function. We analyzed the overlap of the differentially methylated
CpG (DMC) sites from the WGBS data with respect to regions
displaying known chromatin marks in various primary human
blood cell types derived from the Roadmap Epigenomics Project.
Hypermethylation showed strongest enrichment at normally
H3K4me1-marked chromatin across the different blood cell types
(Fig. 3a). Individual comparisons of TET2X and TET2delA
mutation carriers to their age-matched controls showed similar
enrichment (Supplementary Fig. 6-9). The regions with enriched
hypermethylation at H3K4me1 displayed H3K27ac but not
H3K27me3 chromatin mark in the same blood cell types,
implying that methylation was increased in normally active
enhancer regions (Supplementary Fig. 5b). Hypomethylation, on
the other hand, showed strongest enrichment at normally
H3K9me3-marked, transcriptionally repressed chromatin in all
primary human blood cells characterized in the Roadmap
Epigenomics Project (Fig. 3b).
As the enhancer regions with increased methylation are likely
to have lower activity, we studied chromatin immunoprecipita-
tion followed by high-throughput sequencing (ChIP-seq) of
H3K27ac from immortalized lymphoblastoid cell lines. ChIP-seq
enrichment analysis revealed reduced histone acetylation at CpG
islands as a function of methylation increase in TET2delA carriers
as compared to non-carriers (Pearson’s correlation; r=−0.06,
95% confidence interval −0.08 to −0.03, and p-value 2.192 ×
10−06) (Fig. 3c).
Overall DNA methylation level of the hypomethylated CpGs in
partially methylated domains (PMDs) has been proposed to
represent a biomarker for cellular aging16. We extracted
methylation values from the CpGs in the PMD regions and did
not observe methylation difference between the three cancer-free
TET2delA carriers and their age-matched non-carrier family
members in the WGBS data (Supplementary Fig. 10).
We further compared enrichment of hyper- and hypomethyla-
tion at the chromatin marks in blood DNA samples collected at
10 years’ time intervals, available from two carriers (Ly9 and
Ly11) and two non-carriers (Ly8 and Ly10). Age-related
methylation changes showed a similar pattern of enrichment
across the different chromatin marks between TET2delA and
wild-type individuals (Supplementary Fig. 11).
We next examined whether methylation changes in TET2delA
carriers had occurred in hematopoietic cell lineage-specific open
chromatin regions that we derived from public single-cell ATAC-
seq data17. We could observe significantly increased methylation
in the targeted bisulfite sequencing data of TET2delA carriers as
compared to 10 controls in some of the lineage-specific regions,
in particular those found in monocytes, granulocyte/macrophage
progenitors, common lymphoid progenitors, B cells, and
megakaryocyte/erythroid progenitors (two-sided Wilcoxon rank
sum test, false discovery rate (FDR) < 0.05) (Fig. 4a). Because the
emergence of hematopoietic lineages depends on activity of
transcription factors (TFs) such as PU.1, RUNX1/2, CEBPα/β,
GATA1/2, PAX5, and TBX2118, we scrutinized the methylation
statuses of the consensus binding sequences of these TFs within
the lineage-specific open chromatin regions (Supplementary
Fig. 12). We found that many cell-type-specific open chromatin
regions at RUNX2 (binding specificity similar to RUNX1 and
RUNX3), GATA1 (binding specificity similar to GATA2 and
GATA3), and PU.1 binding sequences were significantly enriched
for methylation in the TET2delA carriers (two-tailed permutation
p-values corrected for multiple testing via FDR < 0.05) (Fig. 4b,
Supplementary Table 6).
To scrutinize further the methylation changes related to gene
defects commonly detected in CH and hematological malignan-
cies1, and to provide additional context to findings in TET2
mutation carriers, we derived targeted bisulfite sequencing data
from blood DNA of four DNMT3A germline mutation carriers
and their age-matched controls from the NFID Cohort
(Supplementary Table 3). DNMT3A mutation carriers displayed
increased overall hypomethylation (Fig. 4c) and decreased
methylation at open chromatin regions of all blood cell types
(Supplementary Fig. 13a). Comparison of the effects of TET2 and
DNMT3A loss in mouse hematopoietic stem cells has been
reported19. By enrichment analysis of DMC sites from our WGBS
data, we could observe that hypermethylation in TET2 mutation
carriers was most prominent in regions reported to be sites of
DNMT3A and TET2 competition19 (Supplementary Fig. 13b).
Thus, we next examined whether the methylation changes caused
by human DNMT3A germline mutation could be seen in the
same regulatory regions as in TET2delA carriers. Indeed, the TF-
binding sites at lineage-specific open chromatin regions affected
in the TET2delA carriers were affected also in DNMT3A
mutation carriers, albeit to the opposite direction, showing
decreased methylation (Pearson’s correlation of relative ratios; r
= 0.31, 95% confidence interval 0.03–0.54, and p-value 0.03)
(Fig. 4d).
Blood immune cell phenotyping and single-cell analysis. Leu-
kocyte counts of TET2X and TET2delA carriers were grossly
normal (Supplementary Table 7), whereas further T- and B-
lymphocyte subtyping analyses revealed marked changes (Sup-
plementary Table 8). The two tested TET2delA carriers pre-
viously treated for lymphoma (Supplementary Table 1) displayed
impaired B-cell maturation, compatible with chemotherapy. The
young, approximately 20 years of age TET2delA and TET2X
carriers (Ly14 and Id1) had increased percentages of recent
thymic emigrant and naive subsets of CD3+CD4+ T cells. The
most notable overall changes in the TET2 mutation carriers were
the high percentages of activated (CD38lowCD21low) CD19+ B
cells and low percentages of CD3+CD4/8+CCR7−CD45RA− T
effector memory cells. In addition, the elderly mutation carriers
(Ly1, Ly2, Ly9, and Ly11, aged 36–64 years) exhibited skewing
of CD3+CD8+ T cells toward increased proportions of the
Fig. 2 Heterozygous TET2 loss causes increased DNA methylation. a Count of hypermethylated (dark red bars) and hypomethylated (light gray bars)
cytosines per million tested CpGs in TET2delA carriers (on the left side) and wild-type controls (on the right side). Mutation carriers display elevated
hypermethylation levels in blood as compared to non-carriers. Each sample was compared to the set of five baseline control samples in order to derive
counts of hyper- and hypomethylated CpGs. Methylation profiling of the patients Ly1 and Ly2 was performed from two separate DNA samples extracted in
years 2007 and 2009, others were sampled once. b–f Density plots of differentially methylated CpGs from whole-genome bisulfite sequencing (WGBS).
b–d Pairwise comparison of each TET2delA carrier and age-matched wild-type family member. e Group-wise comparison of three TET2delA carriers to
three age-matched non-carriers of the family. f Pairwise comparison of TET2X carrier and age-matched wild-type individuals from the Northern Finland
Intellectual Disability Cohort. In b–f, X- and Y-axis represent the methylation fraction in TET2 mutation carriers and non-carriers, respectively
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CD3+CD8+CCR7−CD45RA+ terminally differentiated effector
memory cells re-expressing CD45RA (TEMRA) phenotype,
which in the absence of chronic viremia or lymphopenia suggests
immune exhaustion.
Next, we performed single-cell RNA-sequencing analysis of
peripheral blood of the five living TET2delA carriers as well as
three non-carrier family members. The main cell types were
identified through cluster-specific expression patterns and were
present in similar fractions in both groups although individual
variation was observed (Fig. 5a, Supplementary Fig. 14a).
Compatible with the most prominent effect of TET2 loss on
methylation in monocytes (Fig. 4a), TET2 expression was highest
in this cell type and mutation carriers did not display
compensation through increased TET1 or TET3 expression
(Fig. 5b, Supplementary Fig. 14b). A slight decrease in DNMT3A
expression was observed in CD4+ T cells of TET2delA carriers
(Supplementary Fig. 14b). We then scrutinized the differentially
expressed genes between cancer-free TET2delA carriers and age-
matched wild-type individuals (Supplementary Tables 9-12). The
most prominent difference was increased CXCR4 expression,
especially in natural killer (NK) and CD4+/CD8+ T cells













































































































































































Fig. 3 Hypermethylation caused by TET2 loss is enriched at active enhancer regions. a, b Regions with different chromatin marks in 24 different subtypes of
primary human blood cells (each subtype represented by a dot) were available from the Roadmap Epigenomics project. These were compared to the
hyper- and hypomethylated sites detected in blood whole-genome bisulfite sequencing (WGBS) of three cancer-free TET2delA carriers relative to three
age-matched non-carriers. a The hypermethylated sites in TET2delA carriers were characterized by frequent presence of normally H3K4me1-marked
chromatin in primary blood cells. In addition, hypermethylation was enriched strongly at DNaseI hypersensitive and H3K27ac-marked chromatin,
suggesting that methylation was increased in enhancer regions that are normally active. b The hypomethylated sites in TET2delA carriers were enriched at
normally H3K9me3-marked regions that typically represent transcriptionally repressed heterochromatin. Odds ratios and p-values from the Fisher’s exact
test implemented in LOLA R package. c Chromatin immunoprecipitation with an anti-H3K27ac antibody in lymphoblastoid cells from TET2delA carriers
(Ly9, Ly11, and Ly14) was compared to that from wild-type individuals (Ly8 and Ly10). The difference in the enrichment of active H3K27ac-marked
chromatin at CpG islands is displayed as a function of increasing methylation at CpG islands in whole blood of the TET2delA carriers as measured by
WGBS. Negative correlation is stronger at CpG islands outside transcription start sites (TSS). Boxplots show the median, and the first and third quartiles
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TSC22D3 in NK cells, CD8+ T cells, and monocytes of cancer-
free TET2delA carriers (Fig. 5d). TSC22D3 is the gene with the
highest positive correlation to CXCR4 expression at whole
transcriptome level in public expression data from AML (n=
162, The Cancer Genome Atlas data20 in cBioPortal) (Supple-
mentary Fig. 15). Furthermore, we detected reduced expression of
JCHAIN (IgJ), IGLL5, and AL928768.3, a human monoclonal
IgA1-IgA2λ hybrid molecule from IgH locus, especially in B cells
of TET2 mutation carriers (Supplementary Table 11). Compatible
with expression changes of immunoglobulin genes, we detected
significantly elevated methylation in a B-cell-specific open
chromatin region at the promoter of the IGHJ6 gene in TET2delA
carriers (Supplementary Fig. 16, Supplementary Data 1). Analysis
of regulon activity by looking at TFs and their co-expressed cis
target genes revealed 26 TFs with significantly increased and 12
TFs with significantly decreased activity in cancer-free TET2delA
carriers as compared to wild-type individuals, including TBX21
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CD8+ T cells and NK cells (Supplementary Fig. 17, Supplemen-
tary Data 3 and 4).
Clonal hematopoiesis. The analysis of low-frequency variants
from deep exome sequencing revealed CH in two mutation car-
riers (Ly2 and Ly9) (Supplementary Fig. 18). In Ly1, T-cell
receptor gamma rearrangement study had been performed 16
years after lymphoma diagnosis and revealed two clonal PCR
products, compatible with CH also in this patient. No somatic
TET2 mutations were detected, suggesting that complete TET2
loss provided little selective advantage.
Inflammatory responses of monocytes and macrophages. Fuster
et al.5 linked the acceleration of atherosclerotic plaque develop-
ment in Tet2-deficient mice to increased NLRP3 inflammasome-
mediated secretion of IL-1β by macrophages. To explore this
mechanism in human cells, we first primed monocyte-derived
macrophages from cancer-free TET2delA carriers (Ly9, Ly11, and
Ly14) and controls (Ly8 and an unrelated control) with lipopo-
lysaccharide (LPS) and interferon-γ, followed by stimulation with
NLRP3 inflammasome activators. In human macrophages,
priming with LPS induces pro-IL-1β and NLRP3 receptor
mRNAs, but a second NLRP3-activating stimulus is subsequently
required to trigger the caspase-1-mediated proteolytic maturation
and secretion of the inflammasome target cytokines, IL-1β and
IL-1821. TET2delA status did not correlate with elevated secretion
of mature IL-1β or IL-18 in response to any of the studied
canonical or noncanonical activators of the NLRP3 inflamma-
some (Fig. 6a, Supplementary Fig. 19a). A trend toward increased
levels of activated caspase-1 during NLRP3 inflammasome acti-
vation was observed in TET2delA carriers (Fig. 6b). In agreement
with cytokine secretion, the mRNA expression of IL-1β, IL-18,
and NLRP3 inflammasome complex components was comparable
in TET2delA carriers and controls (Fig. 6c, Supplementary
Fig. 19b). In mouse macrophages, TET2 represses IL-1β mRNA
expression indirectly via trichostatin A (TSA)-sensitive histone
deacetylases (HDACs)5. We found that addition of TSA during
LPS+ interferon-γ priming boosted the mRNA induction of IL-
1β and NLRP3 receptor both in TET2delA carriers and controls
(Fig. 6c), but it did not affect the subsequent caspase-1 activation
step (Fig. 6b) or secretion of IL-1β (Supplementary Fig. 19c). To
further corroborate these findings and to ensure that the ex vivo
monocyte-to-macrophage differentiation process caused no
bias, we studied NLRP3 inflammasome responses directly in
blood monocytes isolated from carriers of two further hetero-
zygous TET2-disrupting mutations, TET2del4 and TET2X (two
and one individuals, respectively). Human monocytes (but not
macrophages) express an additional alternative NLRP3 inflam-
masome pathway triggered by prolonged exposure to soluble
LPS21–23, which was studied alongside the canonical ATP-
triggered pathway. We found similar levels of IL-1β secretion in
monocytes from TET2 mutation carriers and controls (Fig. 6d, e).
Finally, we silenced TET2 expression in human peripheral blood
monocyte-derived macrophages from six donors using a pool of
small interfering RNAs (siRNAs) to mimic heterozygous TET2
loss. The mean TET2 knockdown was −59 ± 6% and no com-
pensation or siRNA off-target effects were detected in TET3
expression (Supplementary Fig. 19e), while TET1 expression was
not detected in accordance with previous reports24. In agreement
with our data from TET2 germline mutation carriers, TET2
knockdown had no effect on IL-1β secretion or mRNA induction
(Fig. 6g, Supplementary Fig. 19f).
Aberrantly elevated chemokine expression has also been
reported in Tet2+/− and Tet2−/− mouse macrophages4,5, yet
the TET2delA carriers (n= 3) did not display increased plasma
levels of the key human chemokine IL-8 compared to 12 healthy
volunteers (Fig. 6f), and the same was true when CXCL8/IL-8
transcript levels were measured from TET2delA carrier macro-
phages, as well as after TET2 knockdown by siRNA (Supple-
mentary Fig. 19d and f). Furthermore, the aberrant expression of
pro-inflammatory cytokines and chemokines that was reported in
the context of Tet2+/− mice4,5 was not detected in humans with
RNA-sequencing of TET2delA and control macrophages (Sup-
plementary Data 5). Enrichment analysis of overexpressed genes
(q < 0.1) identified no significant differences between wild-type
and mutant macrophages at baseline nor after LPS+ interferon-γ
treatment (Supplementary Data 5 and 6). Based on previous
works, we selected panels of genes with modified expression
during primary human monocyte-to-macrophage differentiation
and activation25,26. We grouped these genes under cell cycle,
macrophage differentiation, and macrophage M1 polarization,
the latter induced by LPS+ interferon-γ treatment25. Clustering
of the human macrophage RNA-sequencing samples based on
these expression panels found no distinction between the
TET2delA carrier and control groups, indicating similar pace of
differentiation and cytokine-mediated polarization (Supplemen-
tary Fig. 20). Moreover, expression of IL-6 was reported as a
target of TET2-HDAC2-mediated transcriptional repression in
mouse macrophages and dendritic cells5,27. Thus, we further
analyzed in our dataset the expression of IL-6 and a panel of eight
similarly TET2-regulated LPS-inducible target genes reported in
mice27. We could not detect consistently higher levels of IL-6 or
the co-regulated transcripts in TET2delA carrier macrophages
compared to controls (Supplementary Fig. 21) and, in agreement,
Fig. 4 TET2- and DNMT3A-mediated methylation changes are enhanced at open chromatin with master transcription factor-binding sequences (TFBSs).
a Methylation is significantly increased in TET2delA carriers at lineage-specific open chromatin regions of monocytes, granulocyte/macrophage
progenitors (GMPs), common lymphoid progenitors (CLPs), B cells, and megakaryocyte/erythroid progenitors (MEPs). Percentages represent average
methylation differences at the respective open chromatin regions between mutation carriers (Ly1, Ly2, Ly9, Ly11, and Ly14) and 10 controls (Ly8, Ly10, Ly12,
Ly13, HLRCC_N7, and controls 1–5) from targeted bisulfite sequencing. False discovery rate (FDR)-adjusted p-values are from two-sided Wilcoxon rank
sum test. b Schematic of the human hematopoietic cell lineage hierarchy showing the 10 cell types analyzed in a. Black arrows depict emergence of
lineages that showed significant enrichment of methylation at indicated TFBSs at lineage-specific open chromatin regions in the TET2delA carriers. c Count
of hypermethylated (dark red bars) and hypomethylated (light gray bars) cytosines per million tested CpGs in DNMT3A mutation carriers (+/−) and age-
matched controls (+/+) from the Northern Finland Intellectual Disability Cohort. Each sample was compared to the same set of five baseline controls as in
Fig. 2a. d Magnitudes of the methylation changes at master TFBSs located in cell-specific open chromatin regions correlate in TET2 and DNMT3A mutation
carriers, albeit these methylation changes occur toward different directions. X- and Y-axis represent average methylation change in mutation carriers as
compared to controls at open chromatin regions with master TFBS relative to all open chromatin regions in each of the 10 cell types. Each dot of a particular
color represents one of the 10 cell types, respectively. Pearson’s product-moment correlation coefficient (r) and p-value (p) are calculated for the relative
ratios. Methylation values from TET2delA carriers were compared to the 10 controls as in a, and those from DNMT3Amutation carriers to the four controls
as in c. RUNX and GATA represent binding sequences of RUNX1/2/3 and GATA1/2/3, respectively
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Fig. 5 Single-cell RNA-sequencing analysis from peripheral blood. a The main cell types were present in similar numbers between cancer-free TET2delA
carriers (Ly9, Ly11, and Ly14; right) and wild-type individuals (Ly8, Ly10, and Ly13; left). Colors represent blood cells with similar expression profiles in
K-means (K= 10) clustering. Each point represents a cell in the coordinates specified by the two t-SNE (t-distributed stochastic neighbor embedding)
components. b TET2 expression in each of identified cell types represented with unique molecular identifier (UMI) counts. Boxplot shows the mean ±
standard deviation. TET2delA carriers are marked with +/− and wild-type individuals with +/+. c CXCR4 was the most significantly increased transcript in
natural killer (NK) cells and CD8+ T cells [log2 fold change (FC) 2.06], CD4+ T cells (FC 1.12), and all cell types compiled (FC 0.92), in cancer-free
mutation carriers (right) as compared to non-carriers (left). d TSC22D3 expression was significantly increased in NK cells and CD8+ T cells (FC 1.14) and
monocytes (FC 1.1) of mutation carriers
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TET2 knockdown by siRNA in human blood monocyte-derived
macrophages did not affect IL-6 expression (Supplementary
Fig. 19f).
Clinical evaluation of atherosclerosis. Detailed clinical infor-
mation was available from the eight Finnish TET2 mutation
carriers. The mother of Ly1, Ly2, and Ly3, who was a carrier of
TET2delA, died at age 74 years due to pneumonia, with menin-
gioma as a contributing condition according to her death certi-
ficate. Her mutation-free spouse had died of a presumed
myocardial infarction at the age of 45. Ly1, Ly2, and Ly3 all had
received radiotherapy as well as chemotherapy on one to three
different occasions (Supplementary Table 1). Ly1 has a history of
celiac disease and hypercholesterolemia (∼8.5 mmol/l prior to
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has been diagnosed with rheumatoid arthritis, hypercholester-
olemia (total ∼5 mmol/l, high-density lipoprotein ∼ 0.7 mmol/l,
low-density lipoprotein ∼ 3.5 mmol/l prior to medication) and
hypertension. He had smoked 10 pack years but at the age of 63
remains free of clinically manifest atherosclerotic disease. Ly3
died of septic Neisseria meningitidis meningitis free of CVD at the
age of 50. Ly9 is a 41-year-old female ex-smoker, who carries
TET2delA and has remained in good health. Ly11 is a 35-year-old
female TET2delA carrier, diagnosed with mitochondrial ence-
phalomyopathy, lactic acidosis, and stroke-like episodes syn-
drome, inherited from her mother. She has remained free of
atherosclerotic disease. Ly14 is a 19-year-old healthy female
smoker carrying TET2delA mutation. Id1 is a 21-year-old male
who carries de novo TET2X mutation, free of CVD.
We then re-evaluated the existing radiographic data of the
Finnish TET2 mutation carriers. Computed tomography (CT)
scans of chest and abdomen revealed calcified plaques in Ly1 and
Ly2 at age 47 and 48, respectively, and thereafter, whereas Ly3
was lesion-free in five (abdominal, body, and three occasions
chest) CTs between 46 and 48 years of age. Next, we performed
carotid intimal ultrasound to all six living Finnish TET2 mutation
carriers. Measured mean and maximum far wall carotid intima-
media thickness values from the right and left common carotid
artery were evaluated in light of reference values derived from 740
Northern Finland Birth Cohort 1966 study subjects free from
vascular disease or cardiovascular risk factors (K.K., personal
communication). Non-obstructive atherosclerotic plaques as well
as increased intima thickness in carotid arteries were detected in
two subjects (Ly1 and Ly2, 65 and 63 years of age, respectively).
In the four younger subjects (Ly9, Ly11, Ly14, and Id1), carotid
ultrasound was normal.
Discussion
In this study, we identified a family with heterozygous TET2 loss
in seven individuals. Three of these individuals had been diag-
nosed with NLPHL. In addition, an individual with a de novo
TET2 mutation was identified from NFID Cohort data. In our
genome-wide bisulfite sequencing analyses, significant global
hypermethylation was seen in blood of TET2 mutation carriers as
compared to TET2 wild-type cases. Hypermethylation was ele-
vated especially at active enhancer regions. Our findings establish
TET2 as a gene predisposing to familial DNA demethylation
deficiency and hematological aberrations when constitutionally
mutated. We propose that the perturbation in hematopoiesis
caused by reduced TET2 function appears to relate to aberrations
in lineages that require synergistic actions of TET2 and master
TFs involved in hematopoiesis.
Unlike many other lineage-specifying TFs, e.g CEBPα/β and
PAX5, RUNX1/2/3 and PU.1 belong to TFs that have binding
preference to unmethylated DNA28. Interestingly, TET2 has been
shown to directly interact with RUNX129 and PU.130,31. Our data
provided evidence that TET2-mediated DNA demethylation is
required at binding sequences of methyl-sensitive TFs involved in
hematopoiesis, such as RUNX1/2/3 and PU.1, and that loss of one
allele has a significant effect on lineage-specific methylation levels.
When cellular TET2 activity is reduced, the concerted action of
methyl-sensitive TFs and TET2 may become compromised,
leading to increased methylation in key regions for lineage
development. It is important to note that even though we mea-
sured DNA methylation in circulating blood cells, the methyla-
tion differences that had emerged during differentiation remained
in the progeny, and thus could be observed.
Based on regulon-level analysis of single-cell RNA-sequencing
data, we found significantly lowered activity of the T-box TFs
T-box 21 (TBX21) and eomesodermin (EOMES) in circulating
CD8+ T cells and NK cells of the cancer-free TET2delA carriers.
These TFs play crucial and partly overlapping roles in the
development, activation, cytotoxic effector functions, and
exhaustion of CD8+ T cells and NK cells, as well as in the
development and maintenance of the CD8+ T memory cell
pool32–36. These findings may imply dysregulation of cytotoxic
lymphocyte maturation and function, and are compatible with
the changes observed in detailed T-cell phenotyping by flow
cytometry, where reduced CD8+ T effector memory cells and
increased CD8+ exhausted TEMRA phenotype were detected in
the TET2delA carriers. Interestingly, TBX21 has been shown to
recruit TET2 to the lineage-specific signature gene IFNG during
CD4+ T helper 1 cell differentiation, resulting in increased 5-
hmC deposition at IFNG promoter and (−6) enhancer region37.
We could show significantly increased methylation in TET2delA
carriers at binding sequences of TBX21 in NK cells. Thus,
reduced TBX21- and EOMES-mediated transcription in TET2
mutation carriers could conceivably stem from inadequate
recruitment of TET2 to gene regulatory regions by these TFs,
although this remains to be studied in detail.
We observed decreased methylation relative to all open chro-
matin regions in the four DNMT3A germline mutation carriers in
the binding regions of master TFs involved in hematopoiesis,
suggesting that these regions are targets of the joint activity of
TET2 and DNMT3A. When DNMT3A action is reduced, oxi-
dation activity of TET2 leads to reduced levels of 5-mC, and
emergence of 5-hmC and other TET2 oxidation products (toward
unmethylated cytosine), as compared with normal state. Because
this oxidation is a multistep cascade, the clearance of methylation
in these TF-binding regions is likely strongest in hematological
malignancies with concomitant mutations in TET2 and DNMT3A
that indeed are known synergistic drivers of neoplasia38.
Recently, it was proposed that by studying DNA methylation in
late-replicating domains, accumulation of cell divisions and cel-
lular aging could be measured16. We did not observe a difference
in methylation of these domains between TET2 mutation carriers
and their age-matched wild-type controls, suggesting similar
history of cell divisions in both groups. Thus, both the clinical as
well as molecular phenotype of the study subjects are compatible
with low neoplastic potential of an individual TET2+/− cell.
Absence of second hits imply little additional selective value for
loss of both TET2 alleles and, consequently, rare emergence of
TET2-null cells in humans. This is compatible with findings on
Fig. 6 Inflammasome-mediated cytokine response and plasma IL-8 are not elevated in constitutional heterozygous TET2 loss. a–c Monocyte-derived
macrophages from TET2delA mutation carriers and controls were a, b primed for 6 h with lipopolysaccharides (LPS) and interferon-gamma (IFN-gamma)
followed by NLRP3 inflammasome activation with ATP, cholesterol crystals (CHC), or monosodium urate crystals (MSU), or c treated with LPS and IFN-
gamma ± trichostatin A (TSA) for the depicted times. d, e Monocytes from TET2del4 and TET2X mutation carriers and controls and g macrophages
cultured from normal human donors and transfected with control or TET2 siRNAs (SN) were stimulated with LPS+ IFN-gamma+ATP as in a and b. a, d, e,
g Secretion of mature interleukin-1 beta (IL-1B) and IL-18 was measured by enzyme-linked immunosorbent assay (ELISA) from cell culture supernatants, b
cellular caspase-1 activity was detected by flow cytometry (MFI, median fluorescence intensity), and cmRNA expression was analyzed by quantitative PCR
(AU, arbitrary units). f Plasma levels of the CXC chemokine IL-8 were measured by ELISA from TET2delA mutation carriers and healthy volunteers.
Individual data points from each donor are shown with mean values ± s.e.m. f, g Statistical analysis was performed with Wilcoxon rank sum test
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CH1. The emergence of TET2-mutant clones in the elderly may
thus reflect increased resistance to senescence rather than strong
expansive capability, as proposed also by others39.
CVD is the most common cause of death in the Finnish
population (Supplementary Data 7), radio- and chemotherapy
promote atherosclerosis, and also other risk factors such as
positive family history from the paternal side, hypercholester-
olemia, and smoking were present in the TET2delA family.
Considering these, CVD burden in the Finnish mutation carriers
was unremarkable, and we were unable to derive significant
clinical evidence for a role of TET2 germline mutation positivity
in predisposition to atherosclerosis. This result needs to be
interpreted with appropriate caution as the number of individuals
examined was small. CH is associated with CVD3,4, smoking39,40
as well as age, the latter two associating with inflammation and
CVD. In two studies, association between CH and
atherosclerosis-related conditions remained after adjusting for
smoking3,4. In two other studies, Genovese et al.40 found that
excess of mortality in CH patients was explained by a combined
effect of hematological malignancy and smoking, and Zink et al.39
found no significant association between CH and smoking-
associated disease after adjusting for smoking. A more recent
study41 found no evidence of association of TET2- and
DNMT3A-driven CH to CVD in a female cohort. CH and CVD
are both conditions that conceivably associate with quantity of
smoking exposure, not accounted for in the publications thus far,
and strongly with age. An individual’s aging process is not
directly reflected by years, but also nutrition, lifestyle, environ-
ment, and genetics play a role42. It is difficult to perfectly adjust
for these factors, and thus separating two age-related traits in
association analyses is challenging.
Mechanistically, exacerbated IL-1β secretion by macrophages
was proposed to be essential for accelerated atherosclerosis in
context of CH due to Tet2 loss in mice5. However, a more recent
study could not show increased IL-1β secretion in Tet2−/− mouse
macrophages4. Instead, increased CXC chemokine secretion was
proposed as the key factor for accelerated atherosclerosis4, with
increased IL-8/CXCL8 secretion suggested as the possible effector
in humans. We did not find evidence supporting either
mechanism in the six TET2 germline mutation carriers examined,
representing three different truncating mutations. Our results as
such are not discrepant with the mouse work, as the clinical and
molecular consequences of TET2 loss in mice do not need to be
identical to the human phenotype. The effects of TET2 loss are
mediated through hypermethylation within a genome, and the
two genomes were separated tens of millions of years ago. For
example, mice are devoid of TEMRA cells43, which we found to
be elevated in the elderly TET2 mutation carriers and may
influence the human phenotype.
The single-cell RNA-sequencing data revealed significantly
elevated expression of CXCR4 in all blood cells of the TET2delA
individuals, especially in T and NK cells. This chemokine receptor
mediates leukocyte trafficking in response to its ligand CXCL12
and has crucial roles e.g. in B-cell development44. Notably,
CXCR4 knockdown/knockout in bone marrow or in vascular wall
cells aggravates the progression of atherosclerosis in mouse
models45,46. Moreover, a common human CXCR4 variant, C-
allele at rs2322864, is significantly associated with increased risk
of coronary heart disease and with reduced CXCR4 expression in
whole blood and in carotid atherosclerotic plaques45. Thus, the
elevated CXCR4 expression in blood cells of TETdelA carriers
exemplifies one possible atheroprotective effect by TET2 loss that
may help to counterbalance possible proatherogenic effects in
humans. We could also detect reduced expression of immu-
noglobulin genes such as IgJ in B cells of cancer-free TET2delA
carriers. It has been shown that IgJ, Igκ, and VDJ rearranged IgH
co-localize to the same transcription factories47. Furthermore, the
expression of IgJ and Igκ is PU.1 regulated and Igκ is silenced in
mouse early B cells with Tet2/Tet3 loss31,48,49. Altogether, these
data suggest that TET2 has a role in regulating immunoglobulin
genes in human B cells, possibly through cooperation of TET2
and lineage-specific TFs, and/or through high CXCR4
expression50.
It is important to note that the exposure of the germline
mutation carriers to effects of TET2 loss is life-long and extreme,
as compared to the typical CH setting of a minor somatic het-
erozygous TET2-mutant subclone—2% or higher variant allele
frequency39—emerging late in life. Our data raise the possibility,
that circulating TET2-mutant cells may be of limited importance
as an atherosclerosis risk factor, at least in the context of germline
mutation where all cell types carry the mutation. While this
finding does not support a major role of TET2 loss in athero-
sclerosis, it is equally important to note that molecular characters
of CH cells that have accumulated additional changes during
somatic selection may be more aggressive and atherogenic. If so,
the detailed mechanisms need to be determined.
Vitamin C boosts TET2 function51. Thus, adequate vitamin C
intake in the context of hereditary heterozygous TET2 loss-of-
function mutations might reduce risk of neoplasia, a subject that
needs further study. At present, it appears appropriate to at least
advise such individuals to ensure that the daily dose recom-
mended for the general population is reached. In the context of
TET2-mutation-positive CH, prophylactic treatment for athero-
sclerosis using cholesterol-lowering medications or compounds
targeting IL-1β and other inflammatory pathways as proposed2,4,5
would, if effective, be a significant advance. If ineffective, such an
intervention would cause cost and side effects. Thus, it is
important to more thoroughly scrutinize the proposed association
between CH and CVD, and the possible mechanisms underlying
it.
Methods
Study approval. The samples and patient information were obtained with
approval from the ethics committee of the Hospital District of Helsinki and
Uusimaa, the Northern Ostrobothnia Hospital District, the Ethik Kommission
Beider Basel as well as Finnish National Supervisory Authority for Welfare and
Health. Informed consent was obtained for all participants. This study was con-
ducted in accordance with all relevant rules and regulations, including the
Declaration of Helsinki.
Immunohistochemistry. Histopathological analysis of NLPHL samples was per-
formed by an experienced hematopathologist. Formalin-fixed paraffin-embedded
(FFPE) samples were sectioned to 5 μm thickness, and stained with hematoxylin-
eosin, and with antibodies against CD3, CD15, CD20, and CD30 according to
standard procedures at Helsinki University Hospital Pathology Lab.
Detection of genomic regions segregating with lymphoma. Genomic DNA was
extracted from blood samples of three family members, Ly1, Ly2, and Ly8. Blood
sample from Ly3 could not be obtained, since the person is deceased, so a FFPE
tissue was used for DNA extraction. Whole-genome SNP genotypes were obtained
using HumanOmniExpress-FFPE BeadChip (Illumina, Inc., CA, USA) of 693,543
markers. All procedures were performed according to the manufacturer’s
instructions at Finnish Institute for Molecular Medicine (FIMM) Genome and
Technology Centre. Genotype calling and quality control of the data were done
with GenomeStudio Genotyping module version 1.9.4 (Illumina). A parametric
linkage analysis with dominant inheritance model (50% penetrance) was per-
formed using MERLIN52 similar to Saarinen et al.53. Ly8 was considered as
unaffected. Further germline variant analyses were focused on linked regions i.e.
the segregating genomic regions with a positive logarithm of odds score (>0) and a
length of at least 5 cM.
Germline variant analysis. Ly1 genomic DNA library was prepared and
sequenced according to Complete Genomics (Complete Genomics Inc., Mountain
View, CA, USA) paired-end sequencing service protocols. Complete Genomics’
service was conducted with standard coverage: 40× average coverage and 90%
callable diploid loci on the human reference genome. Both read alignment and
variant calling were included in the service.
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Whole-exome sequencing was performed for patients Ly2 and Ly3 by capturing
exomic regions using SureSelect Human All Exon Kit v.1.0 (Agilent Technologies,
Inc., CA, USA) and SeqCap EZ Human Exome Library (Roche Nimblegen, Inc.,
WI, USA), respectively, using the standard protocols. Paired-end sequencing was
performed using Illumina Genome Analyzer II at the Finnish Institute of Molecular
Medicine (Ly2) and Illumina HiSeq2000 at Karolinska Institutet (Sweden; Ly3).
The read lengths were 82 bp (Ly2) and 76 bp (Ly3). The paired-end reads were
quality-controlled using FastQC (www.bioinformatics.babraham.ac.uk/projects/
fastqc), and then aligned to human reference genome version GRCh37 from the
100 Genomes Project (human_g1k_v37.fasta) using an in-house pipeline consisting
of publicly available tools [bwa54 (version 0.5.9) for alignment, Genome Analysis
Toolkit (GATK)55 (version 1.0.5083 for Ly2 and version 1.4 for Ly3) for
realignment around indels, Picard tools (http://picard.sourceforge.net) for
duplicate removal, and samtools56 for sorting and indexing]. Default parameters
were used except for bwa aln -q was set to 5 and -n to 0.06, and bwa sampe max
insert size was set to 800.
We first determined the variants of patient Ly1 inside the linked regions using
the whole-genome sample and a control set consisting of whole genomes and
exomes of in-house Finnish patients’ germline DNA. Additionally, publicly
available data were used (UK10K, www.uk10k.org, and Sequencing Initiative
Suomi, www.sisuproject.fi). In total, the control set consisted of 5197 whole
genomes or exomes. Only variants with zero hits in the control set and Complete
Genomics quality score (VarScoreVAF) higher than 60 were accepted into
downstream analyses. Then, for each remaining variant position in the whole-
genome set, we calculated the coverages of reference and variant reads from the
whole-exome-sequenced patients Ly2 and Ly3, and classified each position based
on coverage and visual inspection into three categories: (i) variant is shared by all
three patients; (ii) variant is not shared by all three; and (iii) not enough evidence
to say whether the variant is shared or not. If the variant read coverage in samples
Ly2 and Ly3 was below four, we put the variant into category (iii). Variants
belonging to sets (i) and (iii) were accepted into downstream analyses. The visual
inspection of the alignments and control filtering was done using the visualization
software BasePlayer57.
Next, a functional effect prediction was done by two different algorithms
(Provean58 and SIFT59). Single-nucleotide or multiple single-nucleotide variants
that were predicted damaging or deleterious by both algorithms, and indels and
stop codon producing variants constitute the set of preliminary shared candidate
variants (Supplementary Table 2).
Finally, we filtered the shared variant list further by using the Exome
Aggregation Consortium (version 0.2) dataset consisting of 60,706 unrelated
individuals’ exomes by allowing no hits in the control set. We further limited the
false positive calls down by using the strict genomic regions accessible to accurate
analysis from the 1000 Genomes Project (phase 1). The remaining variants on the
list were validated by Sanger sequencing. The deletion c.455_462delACAGCCAC
in ABRA was found to be homozygous in the healthy mother of the patients Ly1,
Ly2, and Ly3, excluding it from the final candidate variants (Supplementary
Table 2). Furthermore, the TET2 c.4500delA mutation status of the mother was
examined from archival tissue derived DNA, and she was found to carry the
mutation. All primer sequences used in the validation of the candidate variants are
available in Supplementary Table 13.
Bisulfite sequencing library preparation and data processing. The SureSelect
target enrichment system covering 84.5 Mb (Agilent Technologies, Inc., CA, USA)
was used to prepare bisulfite sequencing libraries from blood DNA of patients (Ly1
and Ly2), healthy family members (Ly8, Ly9, Ly10, Ly11, Ly12, Ly13, and Ly14),
baseline controls (controls 1–5), and DNMT3A mutation carriers and their age-
matched controls (Supplementary Table 3). In addition, blood DNA of a patient
(HLRCC_N7) with germline fumarate hydratase (FH) mutation (c.1027C>T, p.
R343X) was included in the study, because FH-null paragangliomas have been
shown to display genomic hypermethylation60. Two separate bisulfite sequencing
libraries of the patients Ly1 and Ly2 were prepared from DNA samples extracted in
years 2007 and 2009. Sample preparations were done according to the manu-
facturer’s instructions. Illumina paired-end sequencing for targeted libraries from
Ly1, Ly2, Ly8, Ly9, Ly10, and Ly11 was done at Karolinska Institutet using 100 bp
read length and the HiSeq2000 platform. Illumina paired-end sequencing for
targeted libraries from Ly12, Ly13, Ly14, and DNMT3A mutation carriers and their
age-matched controls from NFID cohort was done as a service at BGI (BGI Tech
Solutions Co., Ltd., China) using 126 bp read length and the HiSeq2500 platform.
WGBS library preparations and Illumina sequencing were done as a service at
BGI (BGI Tech Solutions Co., Ltd., China). Bisulfite treatment was done with EZ
DNA Methylation-Gold Kit (Zymo Research, CA, USA) for 300–400 bp size-range
fragments with methylated adapters in 5′ and 3′ ends. Sequencing was done with
the HiSeq X-Ten platform using paired-end 150 bp read length.
Raw sequencing reads were quality and adapter trimmed with cutadapt in Trim
Galore. Trimming of low-quality ends was done using Phred score cutoff 30. Adapter
trimming was performed using the first 13 bp of the standard Illumina paired-end
adapters. Read alignment was done against hg19/GRCh37 reference genome
downloaded from UCSC Genome Browser with Bismark (version v0.14.4)61 and
Bowtie 2 (version 2.2.5)62. Duplicates were removed using the Bismark deduplicate
function. Extraction of methylation calls was done with Bismark methylation
extractor (v0.14.4) discarding first 10 bp of both reads and reading methylation
calls of overlapping parts of the paired reads from the first read (--no_overlap
parameter).
Analysis of targeted bisulfite sequencing data. Detection of DMCs and DMRs
was done with the DSS63 R package (version 2.14.0). Only cytosines with minimal
depth of coverage of six were included. Methylation values were smoothed in 300
bp windows before DMC detection. DMCs were detected on autosomes with Wald
test requiring methylation difference >0.2 and posterior probability >0.99999 in
comparison of each sample against the five baseline control samples (controls 1–5).
For the comparison of number of hyper- or hypomethylated CpGs sites between
five TET2 mutation carriers and five non-carriers, two-tailed Wilcoxon rank sum
tests were performed. DMRs were detected by comparing (i) TET2delA carriers
(Ly1, Ly2, Ly9, Ly11, and Ly14) to wild-type and control samples (Ly8, Ly10, Ly12,
Ly13, HLRCC_N7, and controls 1–5) as well as by comparing (ii) NLPHL cases
(Ly1 and Ly2) to cancer-free TET2delA carriers (Ly9, Ly11, and Ly14). DMRs were
called requiring minimum number of three CpG sites, minimum length 50 bp, and
p-value < 0.01 for (i) and <0.05 for (ii).
ATAC-seq open chromatin regions and fragment counts were downloaded
from GEO accession GSE74912 for hematopoietic cell types17. One-sided
Wilcoxon rank sum test and FDR-adjusted p-value ≤ 0.05 were used to identify
cell-type-specific regions of open chromatin similar to Farlik et al.64. Genomic sites
recognized by each TF (Supplementary Fig. 12)28,65,66 were searched from the
human genome hg19 using program MOODS67 with p-value cutoff of 10−4 and
score cutoff of 5. Open chromatin regions and motif match sites were compared
with BEDtools (v2.26.0) intersect requiring full overlap. The statistical significance
of methylation increase at open chromatin regions with a motif match was assessed
with a permutation test for each cell type. The test statistic was the average
methylation difference at the open chromatin regions between 5 TET2 mutation
carriers, and 10 merged non-carriers and controls. Motif matches were permuted
by randomly repositioning each motif match within the cell-type-specific open
chromatin regions using BEDtools (v2.26.0) shuffle. A total of 1000 permutations
were performed for each motif and cell type, and an empirical p-value calculated as
the proportion of the cumulative distribution where the random test statistic was
higher than the observed methylation difference. For confirmation, 10,000
permutations were also performed for the SPI1 (PU.1) and RUNX2 binding
sequences at each of the cell-type-specific open chromatin regions.
The average methylation values at cell-type-specific open chromatin regions
displayed in Fig. 4a were calculated by taking into account CpG sites with
minimum depth of coverage of 6. Two-sided Wilcoxon rank sum test was used to
test the difference of these average cell-type-specific methylation values between
TET2 mutations carriers (Ly1, Ly2, Ly9, Ly11, and Ly14), and 10 wild-type and
control samples (Ly8, Ly10, Ly12, Ly13, HLRCC_N7, and controls 1–5).
Pearson’s correlation displayed in Fig. 4e was calculated for methylation
changes in mutation carriers as compared to controls at open chromatin regions
with master TF-binding sequence, relative to all open chromatin regions in each of
the 10 cell types. Methylation values from TET2delA carriers (Ly1, Ly2, Ly9, Ly11,
and Ly14) were compared to 10 wild-type and control samples (Ly8, Ly10, Ly12,
Ly13, HLRCC_N7, and controls 1–5), whereas methylation values from DNMT3A
mutation carriers (Id5, Id7, Id9, and Id11) were compared to four controls from
NFID cohort (Id6, Id8, Id10, and Id12). Pearson’s product-moment correlation test
was performed in R resulting in t= 2.2377, df= 48, and p-value= 0.02992.
Analysis of WGBS data. Detection of DMCs was done with the DSS63 R package
(version 2.14.0) at cytosines with minimal depth of coverage of 2. Methylation
values were smoothed in 300 bp windows before DMC detection. DMCs were
detected on autosomes with Wald test requiring methylation difference >0.1 and
posterior probability >0.99.
Enrichment of hyper- and hypomethylated DMCs were analyzed with Locus
Overlap Analysis (LOLA)68 R package (version 1.8.0) using Roadmap Epigenomics
data (https://egg2.wustl.edu/roadmap/data/byFileType/peaks/consolidated/
narrowPeak/) and UCSC features provided in the LOLA extended and core
databases (version 170206), and using differentially methylated and
hydroxymethylated regions from Zhang et al.19 that were converted from mm9 to
hg19 coordinates with liftOver. All CpG sites that were included in the DMC
testing were used as the background set.
Coordinates of Solo-WCGW CpGs [CpGs with the combination of zero
neighboring CpGs (“solo”) and flanked by an A or T (“W”) on both sides] in
common PMDs were downloaded from Zhou et al.16. Boxplots were generated by
considering methylation percentage at CpG sites with minimum depth of coverage
of 6.
Immunophenotyping of mutation carriers. Lymphocyte, B-, and T-cell pheno-
typing were performed as previously published69–71 as a service at Helsinki
University Hospital (analysis codes: 6258smB-Fc, 21388Tdif-Fc, and
8302LyDiff-T). Briefly, for flow cytometry, cells in EDTA samples were stained
using whole blood technique, and analyzed on a FACSCanto II flow cytometer
(Beckton Dickinson Biosciences, San Jose, CA, USA). Fresh heparin-blood
samples or peripheral blood mononuclear cells (PBMCs) were used for B- and
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T-lymphocyte immunophenotyping. Four- or 10-color flow cytometry panel
with monoclonal antibodies (mAbs) against the surface antigens IgM, IgD, CD3,
CD4, CD8, CD16⁄56, CD19, CD21, CD27, CD33, CD34, CD38, CD45, CD56,
CD57, CD133, HLA-DR, CD62L, CD45RA, and CD45RO (BD Biosciences, San
Jose, CA)70. The memory status of T cells was studied with the antibody panel
including anti-CD45, -CD3, -CD4, -CD8 -CD45RA, and -CCR7 (R&D Systems,
Minneapolis, MN, USA)70,71.
Single-cell transcriptome sequencing and analysis. Whole blood was collected
in EDTA-treated collection tubes. Red blood cells were lysed by adding a volume of
ACK lysing buffer (Gibco, New York, NY, US) corresponding to 10–20 times the
volume of the blood sample and incubating at room temperature (RT) for 3 min.
White blood cells were collected by centrifugation at 300 × g for 5 min at RT. The
cells were resuspended in cold phosphate buffered saline (PBS) corresponding to
five times the volume of the whole-blood sample and collected by centrifugation at
4 °C. After resuspending in cold 0.04 % bovine serum albumin/PBS, the cells were
filtered with FlowMiTM Tip strainer of 40 µm porosity (SP Scienceware, Bel-Art
Products, Wayne, NJ, US). Finally, the cells were stained with Trypan Blue
(Invitrogen, Waltham, MA, USA), counted with Countess Automated Cell
Counter (ThermoFisher Scientific), and adjusted to the final concentration of
1 × 106 cells/ml.
Single cells were captured into 10x barcoded gel beads and RNA-sequencing
library preparation was done using Chromium Single Cell 3’ v2 chemistry (10x
Genomics, Pleasanton, CA, USA) at FIMM Single Cell Analytics core facility
(Finland). Sequencing was performed as recommended with 98 bp length of read 2
using HiSeq4000 sequencer (Karolinska Institutet, Sweden). Capture and
sequencing statistics are presented in Supplementary Table 14. Cell Ranger pipeline
(v.2.0.0, 10x Genomics) was used for data processing with default parameters using
prebuild human hg19 genome reference provided by 10x Genomics. Cell types
were identified from K-means (K= 10) clusters utilizing CD3D, NKG7, IL7R,
CD79A, CST3, S100A9, and LYZ marker genes (Supplementary Fig. 14). Data were
separately combined from all eight samples and from six cancer-free family
members with cellranger aggr pipeline. Statistical tests between cancer-free TET2
mutation carriers and wild-type individuals were performed in Loupe Cell Browser
(v1.0.3, 10x Genomics) implementing a variant of the negative binomial exact test,
and for large counts, the fast asymptotic beta test. Resulting p-values were adjusted
for multiple testing using the Benjamini-Hochberg procedure. Twenty most up-
and downregulated genes between cancer-free TET2delA carriers and wild-type
individuals are presented for each major cell type based on fold change regardless
of statistical significance (Supplementary Tables 9-12). XIST and RPS4Y1 were
among the most significantly differentially expressed genes due to gender bias
between TET2delA carriers (100% female) and wild-type individuals.
SCENIC72 was used to identify changes in activity of TFs and their target genes
between cancer-free TET2delA carriers (Ly9, Ly11, and Ly14) and their age-
matched wild-type family members (Ly8, Ly10, and Ly13). In brief, SCENIC
calculates sets of genes that are co-expressed with known TFs and further
retains target genes that show significant motif enrichment of the correct upstream
regulator in cis in the final co-expression modules, “regulons”. The analysis was
limited to TFs that had expression in at least 1% of the cells and at least 199.92
reads (the total number the gene would have, if it was expressed with a value of 3 in
1% of the cells) across all samples, and whose binding motifs were included in the
species-specific databases for RcisTarget (motif collection version 9 including
24,000 motifs). In particular, we used the databases that score the motifs in
gene promoters (up to 500 bp upstream the TSS), and in the 20 kb flanking the TSS
(±10 kbp). First, we calculated SCENIC regulons using single-cell transcriptome
data from the wild-type family members only. Next, activity of each regulon in each
cell was estimated with the AUCell method implemented in SCENIC for both
TET2delA and wild-type samples. Comparisons of the regulon activities
between cells from TET2delA carriers and age-matched family members were
done with Wilcoxon rank sum test. Statistical significance for differential activity
was calculated for 105 TFs that had enough expression and binding motifs
available.
CH detection. Deep exome sequencing was performed from blood DNA samples
of five living TET2 mutation carriers and three wild-type family members extracted
at multiple time points (Ly1 and Ly2 samples from years 2007, 2009, and 2017;
Ly8, Ly9, and Ly11 samples from years 2007 and 2017; Ly10 sample from year
2007; and Ly13 and Ly14 samples from year 2017). Library preparations were
performed with SeqCap EZ Exome v3 (Roche, Switzerland) using six different
index primers per sample for which paired-end Illumina sequencing was done with
75 bp read length and HiSeq4000 sequencer at Karolinska Institutet (Sweden).
After alignment (bwa version 0.7.12), base recalibration (GATK 3.5), realignment
around indels (GATK 3.5), and duplicate removal (MarkDuplicates; Picard Tools
version 1.79), data from libraries with six different indexes were merged together
for variant calling. The merged libraries had >200× average coverage at the capture
target regions (Supplementary Table 15). Due to low allele frequency of variants
expected as indicative of CH40, Unified Genotyper from GATK (version 3.5) was
used to genotype all variants reported in the Catalogue Of Somatic Mutations In
Cancer (COSMIC) v80 (release 20170213). Variants were searched from the strict
genomic regions accessible to accurate analysis (the 1000 Genomes Project Phase
1) excluding variants with StrandOddsRatio > 3.
Functional analyses of human monocytes and macrophages. Functional ana-
lyses were performed (1) in macrophages cultured from fresh blood samples of four
lymphoma-free members of the TET2delA family (Ly8+/+, Ly9+/−, Ly11+/−,
and Ly14+/−) and from an unrelated female control, (2) in monocytes isolated
from frozen PBMCs of two TET2del4 mutation carriers (p226 and p302) and five
unrelated controls, and (3) in monocytes isolated from fresh blood samples of the
carrier of the de novo TET2X mutation (Id1) and a mutation-negative first-degree
relative as control (Id4). TET2 knockdown experiments were performed in mac-
rophages cultured from buffy coat preparations from anonymous blood donors
(Finnish Red Cross Blood Service, Finland).
PBMCs were isolated by density gradient centrifugation in Ficoll-Paque PLUS
(GE Healthcare, Chicago, IL, USA). For macrophage culture, PBMCs were adhered
to culture plates for 1 h, washed three times in PBS, and the adherent monocytes
were differentiated into macrophages via 7 days culture in Macrophage-SFM
medium (Gibco) supplemented with penicillin-streptomycin (Gibco) and 10 ng/ml
recombinant human granulocyte–marophage colony-stimulating factor (Miltenyi
Biotec, Germany). Monocytes were isolated from PBMCs by negative selection
using the Human Pan Monocyte Isolation Kit (Miltenyi Biotec) and magnetic-
activated cell sorting in QuadroMACS (Miltenyi Biotec) separator according to the
manufacturers’ protocols; monocytes were allowed to rest overnight in
Macrophage-SFM medium (Gibco) supplemented with penicillin-streptomycin
(Gibco) before performing the stimulations. For inflammasome activation, cells
were first primed for 6 h with 1 µg/ml LPS from Escherichia coli O111:B4 (Sigma-
Aldrich, St. Louis, MO, USA) and 5 ng/ml (=100 IU/ml) recombinant human
interferon-γ (ImmunoTools GmbH, Germany), in the presence or absence of 1 µM
TSA (InvivoGen, San Diego, CA, USA) where indicated. After priming,
inflammasome activation was triggered by stimulation with 5 mM ATP (Sigma-
Aldrich) for 45 min, 1 mg/ml cholesterol crystals for 16 h, 0.2 mg/ml monosodium
urate (MSU) crystals for 16 h, or by intracellular transfection of 2 μg/ml UltraPure
LPS from E. coli O111:B4 (InvivoGen) with 5 μl/ml Lipofectamine2000
(Invitrogen) for 5 h. Cholesterol (Sigma-Aldrich) at 12.5 g/l in 95% ethanol was
heated to 60 °C, sterile-filtered, crystallized at RT, dried, and ground to a size range
of 1–10 µm using a sterile mortar and a pestle. Uric acid (Sigma-Aldrich) at 5 g/l in
deionized water was heated to 60 °C, adjusted to pH 8.9 with 0.5 N NaOH, and
crystallized at RT. The MSU crystals were recovered by centrifugation, washed,
dried, and sterilized at 180 °C. Endotoxin levels of the cholesterol and MSU crystals
were below the detection limit (<0.03 EU/ml) of Pyrogent gel clot LAL assay
(Lonza, Switzerland). Monocyte inflammasome response to prolonged LPS
exposure was studied by 24 h stimulation with 1 µg/ml LPS from E. coli O111:B4
(Sigma-Aldrich, St. Louis, MO, USA). For TET2 knockdown, macrophages were
transfected twice (on differentiation days 4 and 5) with 100 nM pool of four TET2-
targeted siRNAs (Human TET2 GeneSolution siRNA, Qiagen; Supplementary
Table 16) using the HiPerFect transfection reagent (Qiagen) at 10 µl/ml.
Mature, cleaved forms of IL-1β and IL-18 were detected from cell culture media
supernatants using Human IL-1β/IL-1F2 DuoSet ELISA and Human Total IL-18
DuoSet ELISA, and IL-8 from plasma using Human IL-8/CXCL8 Quantikine HS
ELISA Kit (all from R&D Systems). For quantitative real-time PCR, RNA was
isolated using RNeasy Plus Mini Kit (Qiagen, Germany), followed by cDNA
synthesis with iScript kit (Bio-Rad Laboratories, Inc., Hercules, CA, USA).
Quantitative PCR was performed from 10 ng of cDNA per reaction using
LightCycler480 SYBR Green I master (Roche) and LightCycler96 instrument
(Roche). See Supplementary Table 16 for the primer sequences. The data were
analyzed using LightCycler96 SW 1.1 software (Roche) and relative gene expression
was calculated using the 2(−ΔΔCt) method with RPLP0 used as the endogenous
reference gene. For detection of active caspase-1, primed macrophages were
detached from culture dishes using Accutase Cell Detachment Solution (EMD
Millipore, Billerica, MA, USA), resuspended in culture medium and stimulated
with 5 mM ATP for 15 min at +37 °C. FAM-FLICA Caspase-1 Detection Kit
(ImmunoChemistry Technologies, LLC., Bloomington, MN, USA) was then used
according to the manufacturer protocol. Briefly, 1× FAM-FLICA caspase-
1 substrate was added for 30 min at +37 °C, followed by two washes in 1×
Apoptosis Wash Buffer and staining with propidium iodide. The cells were
analyzed immediately using BD Accuri C6 flow cytometer (BD Biosciences;
instrument maintained by the Biomedicum Flow Cytometry Unit) and the data are
expressed as median fluorescence intensity.
RNA-sequencing libraries from monocyte-derived macrophages from three
individuals with heterozygous TET2 loss (Ly9, Ly11, and Ly14) and two wild-type
controls (Ly8 and an unrelated control) were prepared using ScriptSeq RNA-Seq
Library Preparation Kit and Illumina sequenced with paired-end 75 bp reads at
FIMM (Finland). Reads were quality- and adapter-trimmed with cutadapt version
1.3 in Trim Galore using default parameters. The number of paired-end reads after
trimming varied from 44 to 57M. RNA-seq data were preprocessed using Kallisto
(version 0.43.1) software73. Kallisto quantifications were ran in paired-end and fr-
stranded mode with 100 bootstraps against the GENCODE transcript sequences
(Release 26 mapped to GRCh37). The quantification results were normalized based
on the sleuth (version 0.28.1) R package74. Differentially expressed genes between
TET2 mutants and controls in different conditions were calculated with Wald test
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implemented in sleuth. PANTHER (version 12.0 Released 2017-07-10) protein
class statistical overrepresentation test (release 20170413) was applied to genes with
q-value < 0.1, and b-value (the “beta” value, analogous to fold change) >0 or <0. To
check TET2 c.4500delA allele frequencies, trimmed reads were also aligned with
HISAT275 (version 2.1.0) to GRCh37 Ensembl gene annotations.
TET2 western blot. Proteins were extracted from Epstein-Barr virus (EBV)-
transformed lymphoblastoid cells with RIPA buffer (Sigma-Aldrich) supplemented
with proteinase inhibitor (Roche). Twenty micrograms of protein were loaded into
a 10% Tris-HCl gel (Bio-Rad). A mouse mAb against N-terminal TET2 (1:500
dilution, hT2H21F11, #MABE462; Merck, Kenilworth, NJ, USA) and rabbit
polyclonal antibody against vinculin (1:1000 dilution, H-300, sc-5573; Santa Cruz
Biotechnology, Dallas, TX, USA) was used, at 4 °C overnight incubation. Secondary
antibodies against mouse and rabbit were incubated at RT for 2 h. Proteins were
visualized by Amersham™ ECL Prime Western Blotting Detection System (GE
Healthcare). Immunoblots were quantified with ImageJ software (http://imagej.nih.
gov/ij/). Full gel image of an extended TET2 western blot run with two different
amount of protein extract is shown in Supplementary Fig. 3a.
Chromatin immunoprecipitation. Briefly, EBV-transformed lymphoblastoid cells
from three carriers of TET2delA (Ly9, Ly11, and Ly14) and two wild-type family
members (Ly8 and Ly10) were fixed in 1% formaldehyde for 10 min at RT and
reaction was stopped by adding 0.125 M glycine. Cells were washed in ice-cold PBS
twice and then resuspended in lysis buffer (5 mM PIPES (pH 8.0), 85 mM KCl, and
0.5% NP-40). Lysate was then resuspended in 800 µl of RIPA buffer (1% NP‐40,
0.5% sodium deoxycholate, and 0.1% SDS in PBS) containing protease inhibitors
(Roche). Chromatin was sonicated to an average fragment length of 150–500 bp
using Sonicator Misonix S-4000 with the following parameters: amplitude 30%,
pulse-on time 30 min, pulse-off time 60 min, for a total sonication time of 10 min.
Samples were centrifuged at 13,200 × g for 5 min at 4 °C twice to collect the
supernatant. Dynabeads protein-A magnetic beads (Invitrogen) were washed with
0.05% Tween-20 in PBS. Eight micrograms of antibody Anti-Histone H3 (acetyl
K27) (ab4729; Abcam, UK) were added to the beads and incubated for 15 min on a
rotator at RT. For each sample, 60 µl of the sonicated chromatin were stored as
input fraction, and 750 µl were incubated with the antibody-coupled magnetic
beads on a rotator overnight at 4 °C. After incubation, beads were washed twice
with low-salt washing buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM
Tris-HCl (pH 8.0), and 150 mM NaCl), twice with high-salt washing buffer (0.1%
SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl (pH 8.0), and 500 mM
NaCl), once with lithium chloride washing buffer (1% NP-40, 1% sodium deox-
ycholate, 1 mM EDTA, 20 mM Tris-HCl (pH 8.0), and 500 mM LiCl), and twice
with 1× TE (10 mM Tris-HCl (pH 8.0) and 1 mM EDTA). Antibody-bound
chromatin samples were eluted from the beads by incubating for 1 h at 65 °C in
200 µl of IP elution buffer (1% SDS, 0.1 M NaHCO3, and 10 mM Tris-HCl (pH
7.5)) and crosslinking was reversed by overnight incubation at 65 °C. The eluted
DNA was purified using phenol-chloroform method, followed by library pre-
paration for Illumina HiSeq Rapid paired-end 60 bp sequencing at FIMM
(Helsinki).
Raw sequencing reads were quality and adapter trimmed with cutadapt version
1.16 in Trim Galore version 0.3.7 using default parameters. Trimmed reads were
aligned to hs37d5 reference genome using Bowtie 262 (version 2.1.0). Duplicate
reads were removed with samtools rmdup (v1.7) after which 33–41M
nonredundant reads were left in ChIP and input samples (Supplementary
Table 17). Fragment coverage of paired-end reads was calculated from bam files
with BEDtools genomecov (v2.26.0). Difference of ChIP fragment enrichment
(ChIP fragment coverage− input fragment coverage) as compared to WGBS
methylation difference between TET2delA carriers and wild-type individuals was
calculated at CpG islands (cpgIslandExt) downloaded from UCSC. Only CpG
islands with average ChIP fragment enrichment in wild-type samples ≥10 were
included in correlation testing and in Fig. 3c. Pearson’s product-moment
correlation test was performed in R resulting in t=−4.7389, df= 6770, and p-
value= 2.192e-06.
Material availability. Samples from the NFID cohort are stored in a biobank and
available through an access committee. The other samples have been collected for
the research groups (L.A.A. and R.C.S.). Thus, for the latter any request would need
to be evaluated individually in light of the appropriate local rules and regulations
and unrestricted access cannot be guaranteed.
Code availability
Code for performing the permutation analysis is available upon request.
Data availability
All genetic, expression, methylation, and ChIP-seq data used in the study and in Figs. 2–5
has been submitted to European Genome-phenome Archive (EGA), which is hosted at
the EBI and the CRG, under accession number EGAS00001003454 for long-term
archival. Data that potentially allow identification of individuals must be protected, and
thus, an access committee has been established. ATAC-seq open chromatin regions and
fragment counts for hematopoietic cell types were downloaded from GEO accession
GSE74912. Roadmap Epigenomics data provided in the LOLA extended databases
(version 170206) were downloaded from [http://cloud.databio.org/regiondb/]. The
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